LSV Asset Management Buys 18,500 Shares of LivaNova PLC $LIVN

LSV Asset Management boosted its stake in LivaNova PLC (NASDAQ:LIVN) by 2.7% in the fourth quarter, HoldingsChannel reports. The firm owned 693,110 shares of the company’s stock after acquiring an additional 18,500 shares during the period. LSV Asset Management’s holdings in LivaNova were worth $42,647,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. State of Wyoming bought a new stake in LivaNova in the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC boosted its stake in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares during the last quarter. Quarry LP purchased a new position in shares of LivaNova during the 3rd quarter worth $36,000. UMB Bank n.a. boosted its stake in shares of LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after acquiring an additional 306 shares during the last quarter. Finally, Covestor Ltd boosted its stake in shares of LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after acquiring an additional 392 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LivaNova stock opened at $73.83 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. LivaNova PLC has a 1-year low of $41.01 and a 1-year high of $74.41. The company’s fifty day simple moving average is $65.28 and its 200-day simple moving average is $63.57. The stock has a market capitalization of $4.06 billion, a PE ratio of 37.86 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same quarter in the previous year, the company earned $0.88 EPS. LivaNova’s revenue for the quarter was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities analysts anticipate that LivaNova PLC will post 3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on LIVN. Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research note on Wednesday, February 25th. Piper Sandler reiterated an “overweight” rating and set a $85.00 price target on shares of LivaNova in a research note on Thursday, February 19th. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Robert W. Baird dropped their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Mizuho lifted their price target on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.38.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.